BlossomHill Therapeutics, Inc.
BLSM
NASDAQ·Healthcare·Biotechnology·Mkt cap $640.1M
$22.01
▲ +9.94%
P/E
-30.57
Mkt Cap
$640.1M
52-Wk Range
$15.25–$22.16
52-Week Range
$15.25 - $22.16
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 37.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.0).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+37.6% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying BLSM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
SEP 2, 2026
Reported EPS of -$0.90 vs -$0.93 consensus (+2.8% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+2.8%
Revenue trend · last 1Q
—
Q1 26
$0
Margins · last 1Q
No margin history available.
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Guggenheim · Sep 1, 2026
vs Industry
How BLSM stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.